Meta-analysis of 30 studies shows that ACPA-positive RA patients are marginally more likely to achieve EULAR and ACR20 responses with abatacept (RR 1.18; 95% CI 1.03, 1.35), but not with TNFα-i (RR 0.97; 0.86, 1.10) (compared to ACPA-negative) https://t.co/V5CviFVSGt